View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 3, 2020

Amgen and Adaptive Biotechnologies to develop Covid-19 drug

Amgen has partnered with Adaptive Biotechnologies to develop a drug candidate that could prevent and treat Covid-19 coronavirus infection.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest Covid-19 updates on our timeline.

Amgen has partnered with Adaptive Biotechnologies to develop a drug candidate that could prevent and treat Covid-19 coronavirus infection.

The partners will identify and develop fully human neutralising antibodies that act on SARS-CoV-2.

As part of the alliance, Adaptive’s immune medicine platform to discover virus-neutralising antibodies will combine with Amgen’s immunology and antibody development expertise.

Neutralising antibodies protect healthy cells by hindering the biological function of the virus, noted Amgen.

These antibodies can help treat infected patients and can also be given to individuals at high risk of exposure to the virus, such as healthcare workers.

The companies intend to commence work now and finalise financial terms in the coming weeks.

A memorandum of understanding has been signed to begin work immediately and the parties plan to implement a collaboration and licence agreement.

Amgen chairman and CEO Robert Bradway said: “After swiftly obtaining viral gene sequences from hundreds of patients, Amgen was motivated to use these insights and quickly pair them with our drug development and manufacturing capabilities.

“Working with Adaptive and using their viral-neutralising antibody platform will expedite our ability to bring a promising new medicine into clinical trials as quickly as possible.”

Adaptive’s platform will be used to screen the genetic characteristics of B-cell receptors obtained from people who have recovered from Covid-19 infection.

The approach could help to discover numerous naturally occurring antibodies; the companies will select the one that neutralise SARS-CoV-2.

Amgen will use its antibody engineering and drug development expertise to choose, develop and manufacture antibodies against the virus. The company’s unit deCODE Genetics will offer genetic insights from previously infected Covid-19 patients.

Adaptive Biotechnologies CEO and co-founder Chad Robins said: “This partnership expands our drug discovery capabilities, demonstrating the power and versatility of our immune medicine platform.”

Specific terms of the collaboration are yet to be divulged.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU